Temat: "Interleukin-6" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Autorzy :: Canziani LM; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
Trovati S; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
Brunetta E; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Testa A; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
De Santis M; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Bombardieri E; Scientific Direction, Humanitas Gavazzeni, Bergamo (BG), Italy.
Guidelli G; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Albano G; Anesthesiology and Intensive Care, Humanitas Gavazzeni, Bergamo (BG), Italy.
Folci M; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Squadroni M; Medical Oncology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Beretta GD; Medical Oncology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Ciccarelli M; General Medicine and Pulmonology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Castoldi M; Medical Direction, Humanitas Gavazzeni, Bergamo (BG), Italy.
Lleo A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Aghemo A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Vernile L; Pharmacy, Humanitas Gavazzeni, Bergamo (BG), Italy.
Malesci A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Gastroenterology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Omodei P; General Medicine and Gastroenterology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Angelini C; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Badalamenti S; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Cecconi M; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Anesthesiology andIntensive Care, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy. Electronic address: .
Cremonesi A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Cardiology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Selmi C; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy. Electronic address: .; Pokaż więcej
Corporate Authors :: Humanitas and Gavazzeni / Castelli COVID-19 Task Forces
Źródło :: Journal of autoimmunity [J Autoimmun] 2020 Nov; Vol. 114, pp. 102511. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized/*administration & dosage
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Respiratory Distress Syndrome/*drug therapy
Aged ; Betacoronavirus/immunology ; COVID-19 ; Case-Control Studies ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Female ; Hospital Mortality ; Humans ; Infusions, Intravenous ; Interleukin-6/immunology ; Interleukin-6/metabolism ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Receptors, Interleukin-6/metabolism ; Respiratory Distress Syndrome/diagnosis ; Respiratory Distress Syndrome/immunology ; Respiratory Distress Syndrome/mortality ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Autorzy :: Antwi-Amoabeng D; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Kanji Z; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Ford B; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Beutler BD; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Riddle MS; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Siddiqui F; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.; Pokaż więcej
Źródło :: Journal of medical virology [J Med Virol] 2020 Nov; Vol. 92 (11), pp. 2516-2522. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :: Journal Article; Systematic Review
MeSH Terms :: Hospital Mortality*
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*therapy
Interleukin-6/*antagonists & inhibitors
COVID-19/immunology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/therapy ; Female ; Humans ; Interleukin-6/immunology ; Male ; Observational Studies as Topic ; Receptors, Interleukin-6/antagonists & inhibitors ; Severity of Illness Index ; Time Factors ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Autorzy :: Samaee H; Departement of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Mohsenzadegan M; Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Ala S; Departement of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Maroufi SS; Departemernt of Anesthsia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Moradimajd P; Departemernt of Anesthsia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Electronic address: .; Pokaż więcej
Źródło :: International immunopharmacology [Int Immunopharmacol] 2020 Dec; Vol. 89 (Pt A), pp. 107018. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :: Journal Article; Review
MeSH Terms :: SARS-CoV-2*
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacology ; COVID-19/complications ; Humans ; Interleukin-6/physiology
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?
Autorzy :: Campana P; Department of Translational Medical Sciences, University Federico II, Naples, Italy.
Flocco V; Department of Translational Medical Sciences, University Federico II, Naples, Italy.
Aruta F; Department of Neuroscience, University Federico II, Naples, Italy.
Cacciatore F; Department of Translational Medical Sciences, University Federico II, Naples, Italy.
Abete P; Department of Translational Medical Sciences, University Federico II, Naples, Italy.; Pokaż więcej
Źródło :: Journal of medical virology [J Med Virol] 2021 Feb; Vol. 93 (2), pp. 622-623. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :: Case Reports; Letter
MeSH Terms :: Aldosterone/*blood
COVID-19/*immunology
Cytokine Release Syndrome/*immunology
Interleukin-6/*blood
COVID-19/complications ; COVID-19/diagnosis ; Female ; Guillain-Barre Syndrome/etiology ; Humans ; Middle Aged ; Receptors, Interleukin-6/blood
: Raport

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.
Autorzy :: Werner-Klein M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .
Grujovic A; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Telexos GmbH, Weilheim, Germany.
Irlbeck C; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Obradović M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Wellmera AG, Basel, Switzerland.
Hoffmann M; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Koerkel-Qu H; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Lu X; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Treitschke S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Köstler C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Botteron C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Weidele K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Werno C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Polzer B; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Kirsch S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Gužvić M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Warfsmann J; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Honarnejad K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Czyz Z; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Feliciello G; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Blochberger I; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Grunewald S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Schneider E; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Haunschild G; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Patwary N; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Guetter S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Huber S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Rack B; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.; Department of Gynecology, Ulm University Hospital, Ulm, Germany.
Harbeck N; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.
Buchholz S; Clinic of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany.
Rümmele P; Department of Pathology, University of Regensburg, 93053, Regensburg, Germany.; Institute of Pathology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, 91054, Erlangen, Germany.
Heine N; University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery, University of Regensburg, Regensburg, Germany.
Rose-John S; Institute of Biochemistry, Christian-Albrechts-Universität Kiel, Kiel, Germany.
Klein CA; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. .; Pokaż więcej
Źródło :: Nature communications [Nat Commun] 2020 Oct 05; Vol. 11 (1), pp. 4977. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Signal Transduction*
Interleukin-6/*metabolism
Neoplastic Stem Cells/*metabolism
Neoplastic Stem Cells/*pathology
Bone Marrow/pathology ; Breast/cytology ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Cytokine Receptor gp130/metabolism ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Female ; Humans ; Interleukin-6/genetics ; Mutation ; Neoplasm Metastasis/genetics ; Receptors, Interleukin-6/deficiency ; Receptors, Interleukin-6/metabolism ; Stromal Cells/metabolism ; Tumor Microenvironment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Autorzy :: Kang S; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Tanaka T; Medical Affairs Bureau, Osaka Habikino Medical Center, Osaka 583-8588, Japan.
Inoue H; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Ono C; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Hashimoto S; Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka 583-8588, Japan.
Kioi Y; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Matsumoto H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsuura H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsubara T; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Shimizu K; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Ogura H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsuura Y; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Kishimoto T; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; .; Pokaż więcej
Źródło :: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Sep 08; Vol. 117 (36), pp. 22351-22356. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Signal Transduction*
Cytokine Release Syndrome/*metabolism
Endothelial Cells/*metabolism
Interleukin-6/*metabolism
Plasminogen Activator Inhibitor 1/*metabolism
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Betacoronavirus ; Burns/metabolism ; Burns/pathology ; COVID-19 ; Cells, Cultured ; Coronavirus Infections/drug therapy ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/pathology ; Cytokines/blood ; Cytokines/metabolism ; Endothelial Cells/drug effects ; Female ; Humans ; Inflammation ; Interleukin-6/blood ; Male ; Middle Aged ; Pandemics ; Plasminogen Activator Inhibitor 1/blood ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Receptors, Interleukin-6/metabolism ; Respiratory Distress Syndrome/metabolism ; Respiratory Distress Syndrome/pathology ; SARS-CoV-2 ; Sepsis/metabolism ; Sepsis/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Preemptive interleukin-6 blockade in patients with COVID-19.
Autorzy :: Guillén L; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Padilla S; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Fernández M; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Agulló V; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
García JA; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Telenti G; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
García-Abellán J; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Botella Á; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Gutiérrez F; Clinical Medicine Department, Universidad Miguel Hernández, Ctra. de Valencia (N-322), Km 87, 03550, San Juan de Alicante, Spain. .; Universidad Miguel Hernández, Avda de la Universidad S/N, Elche, 03202, Alicante, Spain. .
Masiá M; Clinical Medicine Department, Universidad Miguel Hernández, Ctra. de Valencia (N-322), Km 87, 03550, San Juan de Alicante, Spain. .; Universidad Miguel Hernández, Avda de la Universidad S/N, Elche, 03202, Alicante, Spain. .; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Oct 08; Vol. 10 (1), pp. 16826. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Betacoronavirus*
Organ Dysfunction Scores*
Antibodies, Monoclonal, Humanized/*pharmacology
Antibodies, Monoclonal, Humanized/*therapeutic use
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Biomarkers/blood ; C-Reactive Protein/analysis ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Female ; Follow-Up Studies ; Humans ; Interleukin-6/blood ; Lymphocyte Count ; Lymphocytes ; Male ; Middle Aged ; Neutrophils ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Spain/epidemiology ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 8 8.

Tytuł :: Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Autorzy :: Della-Torre E; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy .; Università Vita-Salute San Raffaele, Milan, Italy.
Campochiaro C; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Cavalli G; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
De Luca G; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Napolitano A; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
La Marca S; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
Boffini N; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.
Da Prat V; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Di Terlizzi G; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Lanzillotta M; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Rovere Querini P; Università Vita-Salute San Raffaele, Milan, Italy.; Internal Medicine, Diabetes & Endocrinology Unit, San Raffaele Hospital, Milan, Italy.
Ruggeri A; Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
Landoni G; Università Vita-Salute San Raffaele, Milan, Italy.; Department of Anesthesia and Intensive Care, San Raffaele Hospital, Milan, Italy.
Tresoldi M; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Ciceri F; Università Vita-Salute San Raffaele, Milan, Italy.; Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
Zangrillo A; Università Vita-Salute San Raffaele, Milan, Italy.; Department of Anesthesia and Intensive Care, San Raffaele Hospital, Milan, Italy.
De Cobelli F; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
Dagna L; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy .; Università Vita-Salute San Raffaele, Milan, Italy.; Pokaż więcej
Corporate Authors :: SARI-RAF Study Group
SARI-RAF Study Group members
Źródło :: Annals of the rheumatic diseases [Ann Rheum Dis] 2020 Oct; Vol. 79 (10), pp. 1277-1285. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
C-Reactive Protein/*immunology
Coronavirus Infections/*drug therapy
Inflammation/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*drug therapy
Administration, Intravenous ; Anti-Bacterial Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Azithromycin/therapeutic use ; Bacteremia/epidemiology ; Betacoronavirus ; COVID-19 ; Cohort Studies ; Coinfection/epidemiology ; Coronavirus Infections/diagnostic imaging ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Drug Combinations ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Italy ; Lopinavir/therapeutic use ; Lung/diagnostic imaging ; Male ; Middle Aged ; Noninvasive Ventilation ; Oxygen Inhalation Therapy ; Pandemics ; Pneumonia, Viral/diagnostic imaging ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Proportional Hazards Models ; Receptors, Interleukin-6/antagonists & inhibitors ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Severity of Illness Index ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Autorzy :: Saha A; Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.
Sharma AR; Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.
Bhattacharya M; Department of Zoology, Fakir Mohan University, Balasore, Odisha, India.
Sharma G; Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Gangwon-do, South Korea.
Lee SS; Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.
Chakraborty C; Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India. Electronic address: .; Pokaż więcej
Źródło :: Archives of medical research [Arch Med Res] 2020 Aug; Vol. 51 (6), pp. 595-597. Date of Electronic Publication: 2020 May 21.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Betacoronavirus ; COVID-19 ; Humans ; Interleukin-6/immunology ; Pandemics ; Protein Binding ; SARS-CoV-2 ; Signal Transduction
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
Autorzy :: Crisafulli S; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy.
Isgrò V; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy.
La Corte L; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
Atzeni F; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
Trifirò G; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy. .; Pokaż więcej
Źródło :: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2020 Aug; Vol. 34 (4), pp. 415-422.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Coronavirus Infections/*therapy
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*therapy
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19 ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Humans ; Pandemics ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Risk Assessment ; Safety
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Autorzy :: Montesarchio V; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Parrela R; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Iommelli C; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Bianco A; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Manzillo E; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Fraganza F; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Palumbo C; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Rea G; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Murino P; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
De Rosa R; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Atripaldi L; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
D'Abbraccio M; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Curvietto M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Mallardo D; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Celentano E; Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Grimaldi AM; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Palla M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Trojaniello C; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Million-Weaver SL; Independent Investigator, Madison, Wisconsin, USA.
Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy .; Pokaż więcej
Źródło :: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Biomarkers, Pharmacological/*blood
Coronavirus Infections/*drug therapy
Interleukin-6/*blood
Pneumonia, Viral/*drug therapy
Aged ; Antiviral Agents/therapeutic use ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnostic imaging ; Female ; Humans ; Italy ; Lymphocyte Count ; Male ; Middle Aged ; Neutrophils ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnostic imaging ; Receptors, Interleukin-6/antagonists & inhibitors ; Retrospective Studies ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Autorzy :: Mojtabavi H; Universal Scientific Education and Research Network (USERN), Systematic Review and Meta-Analysis Expert Group (SRMEG), Tehran, Iran, Tehran University of Medical Sciences, Children's Medical Center, Research Center for Immunodeficiencies, Tehran, Iran.
Saghazadeh A; Universal Scientific Education and Research Network (USERN), Systematic Review and Meta-Analysis Expert Group (SRMEG), Tehran, Iran, Tehran University of Medical Sciences, Children's Medical Center, Research Center for Immunodeficiencies, Tehran, Iran.
Rezaei N; Tehran University of Medical Sciences, Children's Medical Center, Research Center for Immunodeficiencies, Tehran, Iran, Tehran University of Medical Sciences, School of Medicine, Department of Immunology, Tehran, Iran, Universal Scientific Education and Research Network (USERN), Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Tehran, Iran.; Pokaż więcej
Źródło :: European cytokine network [Eur Cytokine Netw] 2020 Jun 01; Vol. 31 (2), pp. 44-49.
Typ publikacji :: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :: Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal, Humanized/*administration & dosage
Antiviral Agents/*therapeutic use
Betacoronavirus/*immunology
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*drug therapy
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*drug therapy
Aged ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Coronavirus Infections/virology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/mortality ; Cytokine Release Syndrome/virology ; Female ; Gene Expression ; Humans ; Intensive Care Units ; Interleukin-6/genetics ; Interleukin-6/immunology ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Pneumonia, Viral/virology ; Receptors, Interleukin-6/genetics ; Receptors, Interleukin-6/immunology ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Autorzy :: Smetana K Jr; Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic .; BIOCEV, Vestec, Czech Republic.
Brábek J; BIOCEV, Vestec, Czech Republic .; Department of Cell Biology, Faculty of Sciences, Charles University, Prague, Czech Republic.; Pokaż więcej
Źródło :: In vivo (Athens, Greece) [In Vivo] 2020 Jun; Vol. 34 (3 Suppl), pp. 1589-1592.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Coronavirus Infections/*complications
Cytokine Release Syndrome/*etiology
Interleukin-6/*physiology
Pneumonia, Viral/*complications
Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19 ; Clinical Trials as Topic ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/physiopathology ; Cytokine Receptor gp130/antagonists & inhibitors ; Cytokine Receptor gp130/physiology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/physiopathology ; Humans ; Immunotherapy ; Indoles/therapeutic use ; Interleukin-6/antagonists & inhibitors ; Lung/pathology ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/physiopathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Receptors, Interleukin-6/physiology ; Receptors, Virus/drug effects ; Signal Transduction
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Historical overview of the interleukin-6 family cytokine.
Autorzy :: Kang S; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Narazaki M; Department of Advanced Clinical and Translational Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.; Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Metwally H; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Kishimoto T; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka, Japan.; Pokaż więcej
Źródło :: The Journal of experimental medicine [J Exp Med] 2020 May 04; Vol. 217 (5).
Typ publikacji :: Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Interleukin-6/*history
Animals ; Genetic Pleiotropy ; History, 20th Century ; Humans ; Interleukin-6/genetics ; Interleukin-6/metabolism ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Models, Biological ; Mutation/genetics ; Receptors, Interleukin-6/genetics ; Receptors, Interleukin-6/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
Autorzy :: Perricone C; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Conigliaro P; Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Ciccacci C; UniCamillus, Saint Camillus International University of Health Sciences, Rome, and Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
Marcucci E; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Cafaro G; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Bartoloni E; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Perricone R; Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Novelli G; Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
Borgiani P; Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
Gerli R; Rheumatology Unit, Department of Medicine, University of Perugia, Italy. .; Pokaż więcej
Źródło :: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2020 May-Jun; Vol. 38 (3), pp. 580. Date of Electronic Publication: 2020 May 10.
Typ publikacji :: Letter
MeSH Terms :: Adaptor Proteins, Signal Transducing/*genetics
Coronavirus Infections/*drug therapy
Coronavirus Infections/*genetics
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*drug therapy
Pneumonia, Viral/*genetics
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigens, CD/genetics ; Antigens, Differentiation, T-Lymphocyte/genetics ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/genetics ; Betacoronavirus ; COVID-19 ; Humans ; Lectins, C-Type/genetics ; Middle Aged ; Pandemics ; Polymorphism, Single Nucleotide ; Receptors, Interleukin-6/genetics ; SARS-CoV-2
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: [Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia].
Autorzy :: Ulhaq ZS; Department of Biochemistry, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University of Malang, Batu, East Java 65151, Indonesia. Electronic address: .
Soraya GV; Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi 90245, Indonesia.; Pokaż więcej
Transliterated Title :: Tratamiento con anticuerpos anti-receptor de IL-6 para COVID-19 grave y la posible implicación de polimorfismos del gen IL-6 en la nueva neumonía por coronavirus.
Źródło :: Medicina clinica [Med Clin (Barc)] 2020 Dec 24; Vol. 155 (12), pp. 548-556. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :: Polymorphism, Single Nucleotide*
SARS-CoV-2*
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*drug therapy
COVID-19/*therapy
Interleukin-6/*genetics
Promoter Regions, Genetic/*genetics
Receptors, Interleukin-6/*antagonists & inhibitors
Adult ; Antiviral Agents/therapeutic use ; C-Reactive Protein/analysis ; Case-Control Studies ; Clinical Trials as Topic ; Combined Modality Therapy ; Female ; Humans ; Interleukin-6/physiology ; Male ; Middle Aged ; Polymorphism, Genetic ; Respiration, Artificial
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
Autorzy :: Stephen S; Department of General Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Park YA; Department of General Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Chrysostomou A; Department of General Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; Department of Renal Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; The University of Melbourne, Parkville, Victoria, Australia.; Pokaż więcej
Źródło :: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2020 Nov; Vol. 25 (11), pp. 845-849. Date of Electronic Publication: 2020 Sep 17.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Anemia*/etiology
Anemia*/therapy
Coronavirus Infections*/complications
Coronavirus Infections*/diagnosis
Coronavirus Infections*/immunology
Coronavirus Infections*/therapy
Cytokine Release Syndrome*/blood
Cytokine Release Syndrome*/therapy
Cytokine Release Syndrome*/virology
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/blood
Kidney Failure, Chronic*/complications
Kidney Failure, Chronic*/therapy
Pandemics*
Pneumonia, Viral*/complications
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/immunology
Pneumonia, Viral*/therapy
Antibodies, Monoclonal, Humanized/*administration & dosage
Aged ; Blood Transfusion/methods ; C-Reactive Protein/analysis ; COVID-19 ; Female ; Humans ; Immunologic Factors/administration & dosage ; Monitoring, Immunologic/methods ; Renal Dialysis/methods ; Respiration, Artificial/methods ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
Autorzy :: Zhou Z; Program of Advanced Professional Master of Public Health, Global Health, Yale School of Public Health , New Haven, CT, USA.
Price CC; Section of Rheumatology, Allergy & Immunology, Yale University School of Medicine , New Haven, CT, USA.; Department of Allergy and Immunology, VA Medical Center , West Haven, CT, USA.; Pokaż więcej
Źródło :: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2020 Dec; Vol. 29 (12), pp. 1407-1412. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antibodies, Monoclonal/*administration & dosage
COVID-19/*drug therapy
Cytokine Release Syndrome/*drug therapy
Interleukin-6/*antagonists & inhibitors
Pneumonia/*drug therapy
Antibodies, Monoclonal, Humanized/administration & dosage ; COVID-19/epidemiology ; COVID-19/immunology ; Clinical Trials as Topic/methods ; Cytokine Release Syndrome/epidemiology ; Cytokine Release Syndrome/immunology ; Humans ; Interleukin-6/immunology ; Pneumonia/epidemiology ; Pneumonia/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer.
Autorzy :: Dong X; Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China; School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Sun R; Engineering Institute, China Pharmaceutical University, Nanjing, Jiangsu, People's Republic of China.
Wang J; School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China.
Yu S; Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Cui J; Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Guo Z; School of Life Sciences, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
Pan X; School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, People's Republic of China; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Sun J; School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, People's Republic of China; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, People's Republic of China. Electronic address: .
Yang J; Department of General Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, People's Republic of China. Electronic address: .
Pan LL; Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China. Electronic address: .; Pokaż więcej
Źródło :: Biochemical pharmacology [Biochem Pharmacol] 2020 Dec; Vol. 182, pp. 114289. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Breast Neoplasms/*metabolism
Drug Resistance, Neoplasm/*drug effects
Glutathione S-Transferase pi/*biosynthesis
Interleukin-6/*biosynthesis
Macrophages/*metabolism
Animals ; Antibiotics, Antineoplastic/pharmacology ; Antibiotics, Antineoplastic/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Cell Survival/drug effects ; Cell Survival/physiology ; Dose-Response Relationship, Drug ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Drug Resistance, Neoplasm/physiology ; Female ; Glutathione S-Transferase pi/genetics ; Humans ; Interleukin-6/genetics ; MCF-7 Cells ; Macrophages/drug effects ; Mice ; RAW 264.7 Cells
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Genetic polymorphisms in the Interleukins IL1B, IL4, and IL6 are associated with concomitant periodontitis and type 2 diabetes mellitus in Brazilian patients.
Autorzy :: Cirelli T; Department of Diagnosis and Surgery, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.; Department of Morphology, Genetics, Orthodontics and Pediatric Dentistry, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.
Nepomuceno R; Department of Diagnosis and Surgery, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.; Department of Morphology, Genetics, Orthodontics and Pediatric Dentistry, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.
Rios ACS; Department of Morphology, Genetics, Orthodontics and Pediatric Dentistry, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.
Orrico SRP; Department of Diagnosis and Surgery, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.; Advanced Research Center in Medicine, Union of the Colleges of the Great Lakes (UNILAGO), São José do Rio Preto, Brazil.
Cirelli JA; Department of Diagnosis and Surgery, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.
Theodoro LH; Department of Surgery and Integrated Clinic, São Paulo State University-UNESP, School of Dentistry at Araçatuba, Araçatuba, Brazil.
Barros SP; Department of Periodontology, University of North Carolina at Chapel Hill-UNC, School of Dentistry, Chapel Hill, NC, USA.
Scarel-Caminaga RM; Department of Morphology, Genetics, Orthodontics and Pediatric Dentistry, São Paulo State University-UNESP, School of Dentistry at Araraquara, Araraquara, Brazil.; Pokaż więcej
Źródło :: Journal of periodontal research [J Periodontal Res] 2020 Dec; Vol. 55 (6), pp. 918-930. Date of Electronic Publication: 2020 Jul 09.
Typ publikacji :: Journal Article
MeSH Terms :: Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/genetics
Interleukin-1beta*
Interleukin-4*/genetics
Interleukin-6*/genetics
Periodontitis*/complications
Periodontitis*/epidemiology
Periodontitis*/genetics
Brazil ; Case-Control Studies ; Female ; Genetic Predisposition to Disease ; Genotype ; Humans ; Interleukins ; Male ; Polymorphism, Single Nucleotide/genetics ; Smoking
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Interleukin-6"" wg kryterium: Temat

Aktywne filtry:

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język